Clinical trial • Cardiology

DEXAMETHASONE DISODIUM PHOSPHATE for Ischaemic heart disease | Valvular heart disease

Clinical trial of DEXAMETHASONE DISODIUM PHOSPHATE for Ischaemic heart disease | Valvular heart disease.

Overview

Trial Therapeutic Area
Cardiology
Trial Disease
Ischaemic heart disease | Valvular heart disease
Drug Modality
Small molecule

Key dates

Initial CTIS Submission Date
29-09-2024
First CTIS Authorization Date
23-10-2024

Trial design

Randomised, dexamethasone (dexavit, injection/infusion solution) versus placebo (solution for injection); olanzapine (olanzapine glenmark europe 20 mg orodispersible tablets) versus placebo (tablet); flow-targeted versus pressure-targeted hemodynamic management during cpb (no drug); low tidal volume ventilation versus no ventilation during cpb. dexamethasone max daily amount listed as 20 mg; olanzapine max daily amount listed as 10 mg. specific dosing schedule not specified.-controlled trial across 3 sites in Denmark.

Randomised
Yes
Comparator
Dexamethasone (Dexavit, injection/infusion solution) versus placebo (solution for injection); Olanzapine (Olanzapine Glenmark Europe 20 mg orodispersible tablets) versus placebo (tablet); flow-targeted versus pressure-targeted hemodynamic management during CPB (no drug); low tidal volume ventilation versus no ventilation during CPB. Dexamethasone max daily amount listed as 20 mg; Olanzapine max daily amount listed as 10 mg. Specific dosing schedule not specified.
Target Sample Size
1200
Trial Duration For Participant
180

Eligibility

Recruits 1200 No vulnerable population selected; participants are adults (above 18). Informed consent is required from participants; assent not applicable..

Pregnancy Exclusion
Pregnancy or currently breastfeeding
Vulnerable Population
No vulnerable population selected; participants are adults (above 18). Informed consent is required from participants; assent not applicable.

Inclusion criteria

  • {"criterion_text":"-Adult, i.e., above 18 years of age\n-Scheduled for CABG and/or AVR, irrespective of other concomitant valve surgery."}

Exclusion criteria

  • {"criterion_text":"-Acute surgery (i.e. off hours surgery)\n-Recipient of any major organ transplant\n-Obstructive hypertrophic cardiomyopathy, active myocarditis, constrictive pericarditis, untreated hypothyroidism or hyperthyroidism\n-Having received cytotoxic/cytostatic chemotherapy or radiation therapy for treatment of malignancy within the last 6 months\n-Clinical evidence of current malignancy except for basal or localized squamous cell carcinoma, cervical intraepithelial neoplasia or stable prostate cancer.\n-Known narrow-angle glaucoma\n-Known phenylketonuria\n-Pregnancy or currently breastfeeding\n-Known endocarditis at time of screening\n-Previous participation in the trial\n-Active infection, including bacterial, viral, and/or fungal infection\n-Known hepatic cirrhosis\n-Known severe thrombocytopenia with thrombocyte levels < 50 x 109/L\n-Known severe neutropenia with neutrocyte levels < 2 x 109/L\n-On the waiting list for a heart transplant\n-Type I diabetes\n-Known long QT syndrome\n-Known allergy for any of the included study drugs\n-Any condition, where participation in the study, in the investigator's opinion could put the subject at risk, confound the study results or interfere significantly with participation in the study\n-Patients with extracardiac arteriopathy (assessed as part of the preoperative EuroSCORE) will be excluded from the intervention 'flow-targeted vs. pressure-targeted hemodynamic management during CPB'."}

Endpoints

Primary endpoints

  • {"endpoint_text":"-The primary endpoint will be number of days alive and outside hospital within 90 days after surgery.","definition_or_measurement_approach":"Number of days alive and outside hospital within 90 days after surgery (days alive outside hospital within 90 days)."}

Secondary endpoints

  • {"endpoint_text":"-Time in days to occurrence of any component in a composite secondary endpoint during follow-up: a) Death from any cause, b) Stroke, c) Acute kidney injury or d) New onset or worsening heart failure\n-Severe post-operative complications during index admission, defined as a Clavien-Dindo class of 3 to 5.\n-Delirium during the first 7 days after surgery, defined as a positive Confusion Assessment Method for the ICU (CAM-ICU) score or a positive Confusion Assessment Method (CAM) score for the general wards\n-Quality of Recovery-15 (QoR-15) score 3 days, or as soon as possible, after surgery\n-90-day outcomes: Survival, Change in modified Rankin Scale (mRS) from baseline, Health-related quality of life (EQ-5D-5L), Change in self-perceived function \"two simple questions\" and Days alive outside ICU\n-180-day outcomes: Survival","definition_or_measurement_approach":"Composite endpoint: time in days to first occurrence of death, stroke, acute kidney injury, or new/worsening heart failure. Severe complications defined as Clavien-Dindo class 3-5. Delirium defined by CAM-ICU or CAM. QoR-15 measured at day 3 (or as soon as possible). 90-day outcomes include survival, mRS change, EQ-5D-5L, self-perceived function, and days alive outside ICU. 180-day outcome is survival."}

Recruitment

Planned Sample Size
1200
Recruitment Window Months
74
Consent Approach
Informed consent obtained using provided subject information and informed consent forms (L1_ICF and related documents). Participants are adults; assent not applicable.

Geography

Total Number Of Sites
3
Total Number Of Participants
1200

Denmark

Earliest CTIS Part Ii Submission Date
11-10-2024
Latest Decision Or Authorization Date
27-02-2026
Processing Time Days
504
Number Of Sites
3
Number Of Participants
1200

Sites

Site Name
Aarhus Universitet
Department Name
Dept. of Cardiothoracic and Vascular Surgery, Anaesthesia Section
Principal Investigator Name
Peter Juhl-Olsen
Principal Investigator Email
petejuhl@rm.dk
Contact Person Name
Peter Juhl-Olsen
Contact Person Email
petejuhl@rm.dk
Site Name
Rigshospitalet
Department Name
Dept. of Cardiothoracic Anaesthesiology
Principal Investigator Name
Sebastian Wiberg
Principal Investigator Email
sebastian.christoph.wiberg@regionh.dk
Contact Person Name
Sebastian Wiberg
Site Name
Odense University Hospital
Department Name
Department of Anesthesia & Intensive Care Medicine
Principal Investigator Name
Simon Mølstrøm
Principal Investigator Email
simon.molstrom@rsyd.dk
Contact Person Name
Simon Mølstrøm
Contact Person Email
simon.molstrom@rsyd.dk

Sponsor

Primary sponsor

Full Name
Rigshospitalet
Organisation Type
Hospital/Clinic/Other health care facility
Country Of Registered Address
Denmark

Third parties

  • {"country":"Denmark","full_name":"Frederiksberg Hospital","duties_or_roles":"1","organisation_type":"Hospital/Clinic/Other health care facility"}
  • {"country":"Denmark","full_name":"Odense University Hospital","duties_or_roles":"1","organisation_type":"Hospital/Clinic/Other health care facility"}
  • {"country":"Denmark","full_name":"Aarhus Universitet","duties_or_roles":"1","organisation_type":"Educational Institution"}

Investigational products

Investigational Product Name
Dexavit, injektions-/infusionsvæske, opløsning
Active Substance
DEXAMETHASONE DISODIUM PHOSPHATE
Modality
Small molecule
Routes Of Administration
INTRAVENOUS USE
Route
intravenous
Authorisation Status
Authorised (marketing authorisation 55739)
Maximum Dose
20 mg
Investigational Product Name
Olanzapine Glenmark Europe 20 mg orodispersible tablets
Active Substance
OLANZAPINE
Modality
Small molecule
Routes Of Administration
ORAL USE
Route
oral
Authorisation Status
Authorised (EU marketing authorisation EU/1/09/588/012)
Maximum Dose
10 mg
Investigational Product Name
PLACEBO (solution for injection)
Active Substance
PLACEBO
Modality
Other
Routes Of Administration
INTRAVENOUS USE
Route
intravenous
Maximum Dose
20 mg
Investigational Product Name
PLACEBO (tablet)
Active Substance
PLACEBO
Modality
Other
Routes Of Administration
ORAL USE
Route
oral
Maximum Dose
10 mg
Combination Treatment
Yes

Related trials

Other published trials that may interest you.